Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.15 EUR | -10.19% | -8.96% | +80.93% |
01:18pm | TD Cowen Starts NewAmsterdam Pharma With Buy Rating | MT |
May. 09 | Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M | MT |
Chart calendar Frazier Lifesciences Acquisition Corporation
Upcoming events on Frazier Lifesciences Acquisition Corporation
Past events on Frazier Lifesciences Acquisition Corporation
2024-05-14 04:35 pm | RBC Capital Markets Global Healthcare Conference |
2024-05-09 08:00 am | Q1 2024 Earnings Release |
2024-04-07 01:15 pm | American College of Cardiology Scientific Meeting |
2024-03-11 | Jefferies Biotech on the Bay Summit |
2024-03-11 04:00 pm | Leerink Partners Global Biopharma Conference |
2024-03-04 02:10 pm | TD Cowen Health Care Conference |
2024-02-28 08:00 am | Q4 2023 Earnings Release |
2024-02-07 01:00 pm | Guggenheim Healthcare Talks Biotechnology Conference |
2023-11-28 03:30 pm | Piper Sandler Healthcare Conference |
2023-11-16 05:30 am | Jefferies London Healthcare Conference |
2023-11-13 08:00 am | Q3 2023 Earnings Release |
2023-09-27 01:50 pm | Cantor Global Healthcare Conference |
2023-08-07 07:15 am | Q2 2023 Earnings Release |
2023-06-07 03:30 pm | Jefferies Global Healthcare Conference |
2023-06-05 08:00 am | Obicetrapib Phase 2b Clinical Trial Results Call |
2023-06-03 12:00 pm | National Lipid Association Scientific Meeting |
2023-05-08 08:00 am | Q1 2023 Earnings Release |
2023-03-31 08:00 am | Q4 2022 Earnings Release |
2023-03-08 02:50 pm | Cowen Health Care Conference |
2023-02-16 01:00 pm | SVB Securities Global Biopharma Conference |
Annual results
Fiscal Period | December | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Net sales Million EUR | Released Forecast Spread | 0,00 | 97,5 98,2 -0.69% | 13,0 14,2 -8.63% | 10,6 |
EBITDA | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
EBIT Million EUR | Released Forecast Spread | 0,00 | -6,96 7,11 -197.91% | -169 -172 2.01% | -182 |
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | 0,00 | -78,1 7,00 -1215.03% | -163 -169 3.52% | -202 |
Net income Million EUR | Released Forecast Spread | -28,6 | -78,1 7,00 -1215.03% | -163 -167 2.45% | -206 |
EPS EUR | Released Forecast Spread | -2,53 | -0,96 0,08 -1300% | -1,98 -2,03 2.24% | -2,30 |
Announcement Date | 04/08/22 | 31/03/23 | 28/02/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million EUR | Released Forecast Spread | 3,50 | 1,75 | 4,00 7,20 -44.44% | 1,47 | 1,95 | 9,56 | 1,77 | 1,30 1,61 -18.88% | 1,27 | 2,11 | 4,76 | 0,00 | 0,00 |
EBITDA Million EUR | Released Forecast Spread | 27,6 | 29,0 | |||||||||||
EBIT Million EUR | Released Forecast Spread | -25,5 | -25,8 | -34,2 | -36,7 | -48,0 | -51,6 -47,4 -9.01% | -49,5 | -44,3 | -37,0 | -36,4 | -31,6 | ||
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -39,3 | -33,7 | -37,5 | -48,2 | -93,8 -36,2 -158.85% | -46,2 | -39,9 | -34,6 | -31,7 | -26,8 | |||
Net income Million EUR | Released Forecast Spread | -39,2 | -33,7 | -36,1 | -75,1 | -46,9 | -93,8 -43,6 -115.03% | -47,3 | -40,6 | -35,6 | -31,7 | -26,8 | ||
EPS EUR | Released Forecast Spread | -0,45 | -0,41 | -0,43 | -0,92 | -0,56 | -0,99 -0,49 -101.98% | -0,53 | -0,45 | -0,39 | -0,35 | -0,30 | ||
Announcement Date | - | - | 31/03/23 | - | - | 07/08/23 | - | 08/05/24 | - | - | - | - | - |
2024-05-15 | BIOCON LIMITED: Q4 2024 Earnings Release |
2024-05-16 09:00 am | ZEALAND PHARMA A/S: Q1 2024 Earnings Release |
2024-05-17 07:00 am | AUTOLUS THERAPEUTICS PLC: Q1 2024 Earnings Release |
2024-07-23 | VIKING THERAPEUTICS, INC.: Q2 2024 Earnings Release (Projected) |
2024-07-24 | BIOCON LIMITED: Q1 2025 Earnings Release (Projected) |
2024-07-25 01:00 am | ARGENX SE: Q2 2024 Earnings Release |
2024-07-29 | RHYTHM PHARMACEUTICALS, INC.: Q2 2024 Earnings Release (Projected) |
2024-07-29 | NEUROCRINE BIOSCIENCES, INC.: Q2 2024 Earnings Release (Projected) |
2024-07-29 | CEREVEL THERAPEUTICS HOLDINGS, INC.: Q2 2024 Earnings Release (Projected) |
2024-07-30 | CASSAVA SCIENCES, INC.: Q2 2024 Earnings Release (Projected) |
Past sector events for Frazier Lifesciences Acquisition Corporation
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- NAMS Stock
- Calendar Frazier Lifesciences Acquisition Corporation